Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Savient Pharmaceuticals, Inc. (NQ: SVNT)
0.5700 USD  +0.0150 (+2.70%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Savient Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Savient Pharmaceuticals Reports First Quarter 2013 Financial Results
May 15, 2013
from PR Newswire
Semi-Annual Changes to the NASDAQ Biotechnology Index
May 13, 2013
from GlobeNewswire News Releases
First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivus’ Board at the 2013 Annual Meeting
May 01, 2013
from Business Wire News Releases
First Manhattan Comments on Addition to Vivus’ Board of Directors
May 01, 2013
from Business Wire News Releases
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
March 19, 2013
from PR Newswire
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
February 26, 2013
from PR Newswire
Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.
February 19, 2013
from PR Newswire
Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success
February 14, 2013
RDInvesting Provides Stocks Research on Alexza Pharmaceuticals and Savient Pharmaceuticals Read More
from Marketwired News Releases
Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash
January 23, 2013
Five Star Equities Provides Stock Research on Corcept Therapeutics and Savient Pharmaceuticals Read More
from Marketwired News Releases
Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout
January 08, 2013
- First approved therapy in the European Union to address a significant unmet medical need for patients with chronic tophaceous gout Read More
from PR Newswire
Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors
January 08, 2013
from PR Newswire
Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
January 04, 2013
from PR Newswire
Perfect Trade Setups, How to Play STP, AZZ, SVNT and IDIX
January 02, 2013
from Marketwired News Releases
Our Pros Knew X, SVNT, FRO and DANG Would Be Top Gainers on Friday
December 17, 2012
from Marketwired News Releases
Savient Announces the Election of Robert G. Savage to its Board of Directors
December 05, 2012
from PR Newswire
Free Research Reports on CLF, JRCC, SVNT and WPRT Issued by the Bedford Report
November 23, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
November 13, 2012
Post-Hoc Analyses Examining HRQOL, Tophus Reduction and Infusion Reaction Mitigation Presented at the 2012 ACR/ARHP Annual Meeting Read More
from PR Newswire
Biotech Industry Skyrockets in 2012 as FDA Approval Rate Increases
November 12, 2012
Five Star Equities Provides Stock Research on ISIS Pharmaceuticals and Savient Pharmaceuticals Read More
from Marketwired News Releases
New Data Published in Annals of the Rheumatic Diseases Confirm Long-Term Safety and Efficacy of KRYSTEXXA® for the Treatment of Refractory Chronic Gout
November 12, 2012
Two Supportive Posters Presented at the ACR/AHRP Annual Meeting Also Demonstrate Positive Safety and Efficacy Outcomes from the KRYSTEXXA Open-Label Extension Study Read More
from PR Newswire
Free Research Reports on AMCX, ITMN, LEAP and SVNT Issued by the Bedford Report
November 09, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
November 08, 2012
from PR Newswire
Free Research Reports on CLF, IMGN, SVNT and TSYS Issued by the Bedford Report
November 05, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Savient Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call on Thursday, November 8, 2012
October 25, 2012
from PR Newswire
Savient Receives Positive CHMP Opinion for KRYSTEXXA® Approval in the EU
October 19, 2012
If Granted a Marketing Authorization, KRYSTEXXA Will Address a Significant Unmet Need for Certain Patients with Refractory Chronic Gout in the European Union Read More
from PR Newswire
Biotech Industry Looks to Benefit as FDA Speeds Up Process for Drugs for Critical Diseases
October 16, 2012
The Paragon Report Provides Stock Research on Savient Pharmaceuticals and Hemispherx BioPharma Read More
from Marketwired News Releases
Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act
September 28, 2012
Five Star Equities Provides Stock Research on Savient Pharmaceuticals and Dendreon Read More
from Marketwired News Releases
Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 26, 2012
from PR Newswire
Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer
September 24, 2012
from PR Newswire
Savient Announces Multiple Abstracts Related to KRYSTEXXA® in the Treatment of Refractory Chronic Gout to be Presented at the 2012 ACR/ARHP Annual Meeting
September 20, 2012
from PR Newswire
Biotech Industry Looks to Benefit From New Legislation Passed to Help Speed Up FDA Review Process
September 13, 2012
The Paragon Report Provides Stock Research on Savient Pharmaceuticals and Lexicon Pharmaceuticals Read More
from Marketwired News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here